Download presentation
Presentation is loading. Please wait.
Published byIndra Salim Modified over 6 years ago
1
Proteasome Inhibition Attenuates Infarct Size and Preserves Cardiac Function in a Murine Model of Myocardial Ischemia-Reperfusion Injury William E. Stansfield, MD, Nancy C. Moss, MD, Monte S. Willis, MD, PhD, Ruhang Tang, PhD, Craig H. Selzman, MD The Annals of Thoracic Surgery Volume 84, Issue 1, Pages (July 2007) DOI: /j.athoracsur Copyright © 2007 The Society of Thoracic Surgeons Terms and Conditions
2
Fig 1 Experimental design. Proteasome inhibitor PS-519 was administered either 30 minutes prior to left anterior descending coronary artery ligation (A) or at reperfusion (B). (RT-PCR = real time polymerase chain reaction.) The Annals of Thoracic Surgery , DOI: ( /j.athoracsur ) Copyright © 2007 The Society of Thoracic Surgeons Terms and Conditions
3
Fig 2 Infarct analysis 24 hours after ischemia and reperfusion in control and proteasome inhibitor PS-519 treated mice. (A) Cross-sectional photomicrograph (5×) of triphenyl tetrazolium chloride-stained (white) infarcted regions. (B) Percent infarct area relative to ventricular cross-sectional area in sham, control, and PS-519 treated mice (n ≥ 8 for all groups). (C) Percent infarct area relative to area at risk. (*p < 0.05, sham versus control; **p < 0.05 control versus PS-519.) The Annals of Thoracic Surgery , DOI: ( /j.athoracsur ) Copyright © 2007 The Society of Thoracic Surgeons Terms and Conditions
4
Fig 3 Effect of proteasome inhibitor PS-519 on NF-κB related proteins after ischemia-reperfusion. (A) Western blot analysis of myocardial homogenates probed for phospho-p65 after 30 minutes of reperfusion. Real-time polymerase chain reaction of p65 gene expression relative to 18S at the same time points (*p < 0.05, sham versus control; **p < 0.05 control versus PS-519). Western blots for (B) IκBα protein and (C) TNFα at 30 and 60 minutes of reperfusion. The Annals of Thoracic Surgery , DOI: ( /j.athoracsur ) Copyright © 2007 The Society of Thoracic Surgeons Terms and Conditions
Similar presentations
© 2025 SlidePlayer.com. Inc.
All rights reserved.